CD147 expression indicates unfavourable prognosis in prostate cancer.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a membrane glycoprotein implicated in tumor invasion and angiogenesis.
• CD147 overexpression is observed in various human solid tumors, suggesting a role in cancer progression.

Purpose of the Study:

• To investigate the clinicopathological characteristics of CD147 expression in prostate cancer (PCa).
• To assess the clinical significance of CD147 in the histologic classification and prognosis of PCa.

Main Methods:

• Immunohistochemistry was used to detect CD147 protein expression in 62 PCa and 30 benign prostatic hyperplasia (BPH) tissue samples.
• Statistical analysis was performed to correlate CD147 expression with clinicopathological features and patient survival.

Main Results:

• CD147 was positively expressed in 82.3% of PCa cases, significantly higher than in BPH (13.3%).
• CD147 expression strongly correlated with advanced TNM grade, deeper invasion, and higher Gleason and histologic scores.
• Patients with CD147 expression, particularly strong expression, exhibited a poorer prognosis and lower survival rates.

Conclusions:

• CD147 expression is a significant feature in PCa, associated with aggressive tumor characteristics.
• CD147 detection may serve as a valuable biomarker for predicting PCa prognosis.